However, a recent study reported that recombinant C1-INH had a higher ability to deposit on ischemic endothelium and exhibited more potent neuroprotective effects.30 Recombinant C1-INH also had a wider therapeutic window of efficacy (up to 18 h) than plasma-derived C1-INH (shorter than 6 h) in a mouse stroke model.31 Future studies should explore the treatment window and therapeutic effect of recombinant C1-INH in models of TBI. Here, SERPING1 is linked to stroke disorder.